Shayegan B - Search Results

1

2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.

Rendon RA, Selvarajah S, Wyatt AW, Kolinsky M, Schrader KA, Fleshner NE, Kinnaird A, Merrimen J, Niazi T, Saad F, Shayegan B, Wood L, Chi KN, Black P, Sridhar S, Yip S. Rendon RA, et al. Among authors: shayegan b. Can Urol Assoc J. 2023 Oct;17(10):314-325. doi: 10.5489/cuaj.8588. Can Urol Assoc J. 2023. PMID: 37851913 Free PMC article. No abstract available.

2

Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.

Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J. Carver BS, et al. Among authors: shayegan b. J Clin Oncol. 2007 Oct 1;25(28):4365-9. doi: 10.1200/JCO.2007.11.2078. J Clin Oncol. 2007. PMID: 17906201

3

Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Finelli A, et al. Among authors: shayegan b. J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095147

4

Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus.

Bansal RK, Tu HY, Drachenberg D, Shayegan B, Matsumoto E, Whelan JP, Kapoor A. Bansal RK, et al. Among authors: shayegan b. Urology. 2014 Apr;83(4):812-6. doi: 10.1016/j.urology.2013.09.060. Epub 2014 Jan 8. Urology. 2014. PMID: 24411219

5

Editorial comment.

Shayegan B. Shayegan B. Urology. 2009 Nov;74(5):1074-5; author reply 1075. doi: 10.1016/j.urology.2009.05.055. Urology. 2009. PMID: 19883825 No abstract available.

6

Editorial comment.

Shayegan B. Shayegan B. Urology. 2010 Feb;75(2):332-3. doi: 10.1016/j.urology.2009.08.076. Urology. 2010. PMID: 20152482 No abstract available.

7

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J. Masterson TA, et al. Among authors: shayegan b. Urology. 2012 May;79(5):1079-84. doi: 10.1016/j.urology.2011.11.090. Epub 2012 Mar 23. Urology. 2012. PMID: 22446341

8

Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.

Shayegan B, Carver BS, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J. Shayegan B, et al. BJU Int. 2007 May;99(5):993-7. doi: 10.1111/j.1464-410X.2007.06740.x. BJU Int. 2007. PMID: 17437432

9

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B. Gomella LG, et al. Among authors: shayegan b. Can J Urol. 2014 Apr;21(2 Supp 1):1-6. Can J Urol. 2014. PMID: 24775717 Free article.

10

The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies.

Huang WC, Kuroiwa K, Serio AM, Bianco FJ Jr, Fine SW, Shayegan B, Scardino PT, Eastham JA. Huang WC, et al. Among authors: shayegan b. J Urol. 2007 Apr;177(4):1324-9; quiz 1591. doi: 10.1016/j.juro.2006.11.069. J Urol. 2007. PMID: 17382724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page